The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture ...

A research team co-led by scientists at the University of Arizona College of Medicine—Tucson found that an osteoporosis drug ...

Calcium and magnesium each offer health benefits, so does taking them together increase their impact on your health? Learn ...

Skeletal conditions such as developmental dysplasia of the hip (DDH), osteoporosis, and osteoarthritis affect millions ...

The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent ...

The Osteoporosis Society of the Philippines Foundation Inc. (OSPFI) estimates that by 2050, around 10.2 million Filipinos ...

Non-invasive therapeutics for anti-osteoporosis treatment and fracture healing are available in both oral and injectable ...

The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis ...

Celltrion’s two biosimilar treatments for treating osteoporosis and preventing bone metastasis complications in cancer ...

A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...